# Verde Clean Fuels, Inc.: financial statements, quarterly

VGAS · Nasdaq · CIK 1841425 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vgas.md) · [Financials](/companies/vgas/financials.md) · [Filings](/companies/vgas/filings.md) · [Insiders](/companies/vgas/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vgas/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [78.3](/filings/0001213900-24-097136.md) | [82.4 d](/filings/0001628280-25-015480.md) | [85.8](/filings/0001628280-25-025504.md) | [173](/filings/0001628280-25-040155.md) | [91.0](/filings/0001628280-25-052351.md) | [101 d](/filings/0001628280-26-021763.md) | [183](/filings/0001628280-26-033746.md) | [145](/filings/0001628280-26-055390.md) | [128](/filings/0001628280-25-052351.md) | [134 d](/filings/0001628280-26-021763.md) | [181](/filings/0001628280-26-033746.md) | [165](/filings/0001628280-26-055390.md) |
| Operating income | $k | [(2,589)](/filings/0001213900-24-097136.md) | [(2,363) d](/filings/0001628280-25-015480.md) | [(2,875)](/filings/0001628280-25-025504.md) | [(3,162)](/filings/0001628280-25-040155.md) | [(2,785)](/filings/0001628280-25-052351.md) | [(2,835) d](/filings/0001628280-26-021763.md) | [(3,181)](/filings/0001628280-26-033746.md) | [(3,239)](/filings/0001628280-26-055390.md) | [(2,880)](/filings/0001628280-25-052351.md) | [(7,153) d](/filings/0001628280-26-021763.md) | [(2,854)](/filings/0001628280-26-033746.md) | [(2,524)](/filings/0001628280-26-055390.md) |
| Interest expense | $k | [67.4](/filings/0001213900-24-097136.md) | [0.0 d](/filings/0001628280-25-015480.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [119](/filings/0001213900-24-097136.md) | [47.1 d](/filings/0001628280-25-015480.md) | [0.0](/filings/0001628280-25-025504.md) | [(13.9)](/filings/0001628280-25-040155.md) | [0.0](/filings/0001628280-25-052351.md) | [65.0 d](/filings/0001628280-26-021763.md) | [53.0](/filings/0001628280-26-033746.md) | [(28.0)](/filings/0001628280-26-055390.md) | [104](/filings/0001628280-25-052351.md) | [(23.0) d](/filings/0001628280-26-021763.md) | [46.0](/filings/0001628280-26-033746.md) | [(106)](/filings/0001628280-26-055390.md) |
| Net income | $k | [(773)](/filings/0001213900-24-097136.md) | [(647) d](/filings/0001628280-25-015480.md) | [(772)](/filings/0001628280-25-025504.md) | [(904)](/filings/0001628280-25-040155.md) | [(778)](/filings/0001628280-25-052351.md) | [(880) d](/filings/0001628280-26-021763.md) | [(1,247)](/filings/0001628280-26-033746.md) | [(1,260)](/filings/0001628280-26-055390.md) | [(1,155)](/filings/0001628280-25-052351.md) | [(3,296) d](/filings/0001628280-26-021763.md) | [(1,207)](/filings/0001628280-26-033746.md) | [(907)](/filings/0001628280-26-055390.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001213900-23-086139.md) | not reported | [(0.13)](/filings/0001213900-24-042980.md) | not reported | not reported | not reported | [(0.08)](/filings/0001628280-26-033746.md) | [(0.07)](/filings/0001628280-26-055390.md) | not reported | not reported | [(0.05)](/filings/0001628280-26-033746.md) | [(0.04)](/filings/0001628280-26-055390.md) |
| Basic EPS | $ per share | [(0.13)](/filings/0001213900-23-086139.md) | not reported | [(0.13)](/filings/0001213900-24-042980.md) | not reported | not reported | not reported | [(0.08)](/filings/0001628280-26-033746.md) | [(0.07)](/filings/0001628280-26-055390.md) | not reported | not reported | [(0.05)](/filings/0001628280-26-033746.md) | [(0.04)](/filings/0001628280-26-055390.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [31.2](/filings/0001213900-23-086139.md) | [28.8](/filings/0001628280-25-015480.md) | [25.9](/filings/0001213900-24-042980.md) | [23.2](/filings/0001213900-24-067909.md) | [21.7](/filings/0001213900-24-097136.md) | [19.0](/filings/0001628280-26-021763.md) | [65.3](/filings/0001628280-25-025504.md) | [62.1](/filings/0001628280-25-040155.md) | [59.4](/filings/0001628280-25-052351.md) | [57.2](/filings/0001628280-26-055390.md) | [54.3](/filings/0001628280-26-033746.md) | [53.5](/filings/0001628280-26-055390.md) |
| Current assets | $m | [32.1](/filings/0001213900-23-086139.md) | [29.3](/filings/0001628280-25-015480.md) | [27.4](/filings/0001213900-24-042980.md) | [25.0](/filings/0001213900-24-067909.md) | [22.8](/filings/0001213900-24-097136.md) | [20.2](/filings/0001628280-26-021763.md) | [67.2](/filings/0001628280-25-025504.md) | [64.0](/filings/0001628280-25-040155.md) | [61.5](/filings/0001628280-25-052351.md) | [57.9](/filings/0001628280-26-055390.md) | [55.3](/filings/0001628280-26-033746.md) | [54.3](/filings/0001628280-26-055390.md) |
| Total assets | $m | [34.6](/filings/0001213900-23-086139.md) | [31.9](/filings/0001628280-25-015480.md) | [30.1](/filings/0001213900-24-042980.md) | [27.8](/filings/0001213900-24-067909.md) | [25.9](/filings/0001213900-24-097136.md) | [23.6](/filings/0001628280-26-021763.md) | [71.3](/filings/0001628280-25-025504.md) | [68.7](/filings/0001628280-25-040155.md) | [67.2](/filings/0001628280-25-052351.md) | [60.2](/filings/0001628280-26-055390.md) | [57.9](/filings/0001628280-26-033746.md) | [56.8](/filings/0001628280-26-055390.md) |
| Current liabilities | $m | [3.8](/filings/0001213900-23-086139.md) | [2.5](/filings/0001628280-25-015480.md) | [3.0](/filings/0001213900-24-042980.md) | [3.3](/filings/0001213900-24-067909.md) | [3.5](/filings/0001213900-24-097136.md) | [2.8](/filings/0001628280-26-021763.md) | [3.5](/filings/0001628280-25-025504.md) | [2.9](/filings/0001628280-25-040155.md) | [3.1](/filings/0001628280-25-052351.md) | [2.1](/filings/0001628280-26-055390.md) | [1.5](/filings/0001628280-26-033746.md) | [2.1](/filings/0001628280-26-055390.md) |
| Total liabilities | $m | [3.8](/filings/0001213900-23-086139.md) | [3.1](/filings/0001628280-25-015480.md) | [3.1](/filings/0001213900-24-042980.md) | [3.5](/filings/0001213900-24-067909.md) | [3.6](/filings/0001213900-24-097136.md) | [2.9](/filings/0001628280-26-021763.md) | [3.5](/filings/0001628280-25-025504.md) | [3.0](/filings/0001628280-25-040155.md) | [3.1](/filings/0001628280-25-052351.md) | [2.1](/filings/0001628280-26-055390.md) | [1.6](/filings/0001628280-26-033746.md) | [2.1](/filings/0001628280-26-055390.md) |
| Shareholders' equity | $m | [30.7](/filings/0001213900-24-097136.md) | [28.8](/filings/0001628280-26-021763.md) | [27.0](/filings/0001628280-25-040155.md) | [24.4](/filings/0001628280-25-052351.md) | [22.3](/filings/0001628280-25-052351.md) | [20.7](/filings/0001628280-26-055390.md) | [67.7](/filings/0001628280-26-055390.md) | [65.7](/filings/0001628280-26-055390.md) | [64.0](/filings/0001628280-25-052351.md) | [58.1](/filings/0001628280-26-055390.md) | [56.3](/filings/0001628280-26-055390.md) | [54.7](/filings/0001628280-26-055390.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,992) d](/filings/0001213900-24-097136.md) | [(2,319) d](/filings/0001628280-25-015480.md) | [(2,829)](/filings/0001628280-25-025504.md) | [(2,188) d](/filings/0001628280-25-040155.md) | [(1,638) d](/filings/0001628280-25-052351.md) | [(2,225) d](/filings/0001628280-26-021763.md) | [(3,702)](/filings/0001628280-26-033746.md) | [(2,181) d](/filings/0001628280-26-055390.md) | [(1,680) d](/filings/0001628280-25-052351.md) | [(1,326) d](/filings/0001628280-26-021763.md) | [(2,617)](/filings/0001628280-26-033746.md) | [(826) d](/filings/0001628280-26-055390.md) |
| Capital expenditure | $k | not reported | [55.9 d](/filings/0001628280-25-015480.md) | [8.3](/filings/0001628280-25-025504.md) | [544 d](/filings/0001628280-25-040155.md) | [893 d](/filings/0001628280-25-052351.md) | [1,105 d](/filings/0001628280-26-021763.md) | [473](/filings/0001628280-26-033746.md) | [1,547 d](/filings/0001628280-26-055390.md) | [2,438 d](/filings/0001628280-25-052351.md) | [3,227 d](/filings/0001628280-26-021763.md) | [458](/filings/0001628280-26-033746.md) | [1.0 d](/filings/0001628280-26-055390.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2021-03-31) | Q1 FY2022 (2022-03-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3.8](/filings/0001213900-22-025957.md) | [4.5](/filings/0001213900-22-025957.md) | [6.1](/filings/0001213900-24-042980.md) | [6.1](/filings/0001213900-23-067127.md) | [6.2](/filings/0001213900-23-086139.md) | [6.2](/filings/0001213900-24-042980.md) | [14.8](/filings/0001628280-26-033746.md) | [18.8](/filings/0001628280-26-055390.md) | [22.1](/filings/0001628280-26-033746.md) | [22.1](/filings/0001628280-26-055390.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.